A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases

por Huoponen, Saara, Blom, Marja
Publicado 2015

Healthcare costs and productivity losses in treatment-resistant depression in Finland

por Rannanpää, S., Taipale, H., Tanskanen, A., Lähteenvuo, M., Huoponen, S., Tiihonen, J.
Publicado 2022

Effects of pre-emptive pregabalin and multimodal anesthesia on postoperative opioid requirements in patients undergoing robot-assisted laparoscopic prostatectomy

por Sisa, K., Huoponen, S., Ettala, O., Antila, H., Saari, T. I., Uusalo, P.
Publicado 2021

Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland – a matched cohort study

por Taipale, Heidi, Lähteenvuo, Markku, Tanskanen, Antti, Huoponen, Saara, Rannanpää, Saara, Tiihonen, Jari
Publicado 2022

The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review

por Joensuu, Jaana T., Huoponen, Saara, Aaltonen, Kalle J., Konttinen, Yrjö T., Nordström, Dan, Blom, Marja
Publicado 2015

Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease

por Huoponen, Saara, Eberl, Anja, Räsänen, Pirjo, Roine, Risto P., Sipponen, Taina, Arkkila, Perttu, Blom, Marja
Publicado 2020

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis

por Huoponen, Saara, Aaltonen, Kalle J., Viikinkoski, Jaana, Rutanen, Jarno, Relas, Heikki, Taimen, Kirsi, Puolakka, Kari, Nordström, Dan, Blom, Marja
Publicado 2019